Thymosin Alpha-1 dosage

Thymosin Alpha-1 subcutaneous — zadaxin (chronic hepatitis b) dosage

For chronic hepatitis B, Singapore ZADAXIN product information specifies 1.6 mg subcutaneously twice weekly for 6–12 months. This indication-specific schedule does not define a general immune-wellness course. A separate reported subcutaneous progression lists 300 mcg daily in week 1 and 500 mcg daily thereafter over 8–16 weeks. This lower-dose daily pattern is distinct from the indication-specific 1.6 mg twice-weekly ZADAXIN regimen and does not replace it.[9][10]

Thymosin alpha-1 is an immune-signaling peptide involved in T-cell and innate-immune responses. Regimens depend on the indication and locally authorized product.[1][2][3]

Frequency and timing

Morning is the usual timing.[4][5][1]

Cycle length and breaks

Subcutaneous — ZADAXIN (chronic hepatitis B): 6–12 months. A standard break interval between courses is not established.[9]

Approval and product quality

Thymosin Alpha-1 is not an FDA-approved drug.[5][6][7][8]

Side effects and long-term safety

Injection reactions, fatigue, headache and nonspecific immune-treatment symptoms are practical tolerability concerns. Optimal duration, repeated-cycle safety, interactions with immunotherapies and U.S. compounded-product consistency remain uncertain.[4][1][2][3]

Route-specific dosing limits

Immune status, concurrent therapy, and product quality drive the main safety decisions. Additional schedules attributed to Everything Peptide are reported patterns; citing research does not make these schedules clinically established or approved product instructions.[4][1][2][3][10]